Despite what the name suggests, Polycystic Ovary Syndrome isn’t just about ovaries—or cysts, for that matter. In fact, many people diagnosed with PCOS don’t have any ovarian cysts at all. Confusing? You’re not alone. The name dates back to how the condition was first described, but science has come a long way since then. Today, we understand that PCOS is really a complex hormonal and metabolic condition that affects far more than reproductive health.
At its core, PCOS is about hormonal imbalance. When key hormones like insulin, androgens (like testosterone), and others are out of sync, they can create a domino effect throughout the body. This hormonal miscommunication can lead to irregular periods, acne, weight changes, hair loss or excess hair growth, difficulty with ovulation or fertility—and that’s just the shortlist. But here’s the thing: PCOS doesn’t follow a single pattern. Some women experience textbook symptoms. Others don’t fit the mold at all. That’s part of what makes PCOS so challenging—and why understanding your unique experience matters.
So, how can the PCOS Association help?
We’re here to offer more than definitions. We’re here to offer direction. Whether you’re newly diagnosed, still searching for answers, or years into your journey and feeling stuck, we’re committed to helping you make sense of PCOS—and make progress.
Here’s what you’ll find at PCOSA:
✅ Reliable, science-backed information about what PCOS is (and isn’t)
💬 Supportive communities of people who understand exactly what you’re going through
🧬 Resources for navigating fertility, metabolic health, nutrition, and more
🧠 Education for providers who want to better support their PCOS patients
🙋♀️ Advocacy to make sure PCOS is recognized, researched, and respected
No fluff. No fad cures. Just real support, grounded in evidence and compassion.
At PCOSA, we believe every person with PCOS deserves to be informed, empowered, and heard. Wherever you are in your journey, we’re honored to walk with you.
pcos: Latest results from PubMed
CONCLUSION: Non-obese women with PCOS had a higher prevalence of fatty liver, with minor differences in metabolic parameters, and BMI partly mediated these associations.
Published on: Thu, 15 Jan 2026 06:00:00 -0500
Authors: Fateme Amiri, Homeira Rashidi, Leila Moradi, Seyedbahman Ghderian, Reyhanesadat Taghavi,
Background Menstrual disorders such as dysmenorrhea, menorrhagia, oligomenorrhea, and premenstrual syndrome are believed to be the most common yet under-recognized causes of morbidity in adolescent girls. Many adolescents around the world experience menstrual dysfunction, and in India, cultural stigma, poor awareness, and nutritional imbalance are believed to exacerbate the burden. Despite national initiatives focusing on menstrual hygiene and anemia prevention, only a few studies in India have...
Published on: Thu, 15 Jan 2026 06:00:00 -0500
Authors: Pragya Prem, Veena S R, Meena T S, Revathy T G,
No abstract
Published on: Thu, 15 Jan 2026 06:00:00 -0500
Authors: Min Xing, Jing Li, Xiaolan Wu, Ruyi Zhang, Lan Li, Huiping Liu,
CONCLUSIONS: Valproate exposure was associated with an increased risk of PCOS. The risk was especially pronounced during current and cumulative exposure, whereas overall cumulative exposure suggested increased risk at higher thresholds. These findings suggest that PCOS risk may be driven by acute pharmacological effects, although long-term cumulative use may also contribute. The results reinforce recommendations to avoid valproate in women of reproductive age when possible.
Published on: Wed, 14 Jan 2026 06:00:00 -0500
Authors: Maria Holmskov, Jakob Christensen, Mie Frederiksen Larsen, Ann-Eva Christiansen, René Ernst Nielsen,
CONCLUSION: In a 12-week cross-over feasibility study, TRE was a safe and feasible intervention. Recruitment was challenging and with limited numbers, the TRE group showed a decrease in HbA1c and anthropometric indices compared to the 'ad libitum' group.
Published on: Wed, 14 Jan 2026 06:00:00 -0500
Authors: Ruairí Floyd, Adam Dyer, James Gibney, Fatimah Alawami, Lisa Owens, Niamh Phelan, Ana Rakovac, Patrick Swan, Carel W LeRoux, Lucy Ann Behan, Sinead N Duggan,
Polycystic ovary syndrome (PCOS) accelerates ovarian follicular depletion through atresia. This study investigated the therapeutic potential of aqueous (AE) and hydroethanolic (HEE) extracts of Cymbopogon citratus in mitigating PCOS-induced ovarian damage (specifically ferroptosis, apoptosis, and oxidative stress) in a rat model of PCOS. PCOS was induced by oral administration of letrozole (1 mg/kg/day for 21 days), followed by treatment with AE or HEE (100, 200, or 400 mg/kg/day for 20 days)...
Published on: Wed, 14 Jan 2026 06:00:00 -0500
Authors: Vanis Slauvers Akago, Marie Alfrede Mvondo, Sefirin Djiogue, Stephen Lacmata Tamekou, Nina-Sonia Messongue Mbollo, Josue Jobin Biba, Agatha Yelah Ntumnyuy, Lylie Gisèle Atsafack Mboudem, Perpetue Atsama Mbede, Christophe Mezui, Hélène Carole Edima-Durand, Jules-Roger Kuiate, Dieudonné Njamen,
CONCLUSION: This study showed that the combined effect of Nigella sativa and Salvia officinalis was better able to treat PCOS and may replace Metformin to improve PCOS-induced abnormalities.
Published on: Wed, 14 Jan 2026 06:00:00 -0500
Authors: Hiba Faour, Samah Hachem, Miriam Al Battal, Jamilah Borjac,
CONCLUSIONS: Naringenin may ameliorate PCOS by downregulating hypothalamic Kiss1 and Cgrp gene expression in rats. These results suggest a novel mechanism of naringenin's action and highlight its potential for clinical application.
Published on: Wed, 14 Jan 2026 06:00:00 -0500
Authors: Manizheh Habibi, Fariba Mahmoudi, Khadijeh Haghighat, Homayoun Khazali,
BACKGROUND: Polycystic ovary syndrome (PCOS) affects women globally, but its prevalence across World Health Organization (WHO) regions has not previously been reported.
Published on: Tue, 13 Jan 2026 06:00:00 -0500
Authors: Adriana C H Neven, Maria Forslund, Sanjeeva Ranasinha, Parneet Sethi, Raja Ram Dhungana, Aya Mousa, Chau T Tay, Helena Teede, Jacqueline A Boyle,
Female infertility is a multifactorial condition with complex biological and clinical underpinnings. Biologically, female-related infertility may stem from disruptions in the hypothalamic-pituitary-ovarian (HPO) axis, impaired folliculogenesis, oocyte maturation defects, uterine abnormalities, endometrial dysfunction, and fallopian tube abnormalities. This review highlights key genetic mechanisms contributing to reproductive dysfunction and their relevance to diagnosis and treatment. Chromosomal...
Published on: Tue, 13 Jan 2026 06:00:00 -0500
Authors: Mitko Madjunkov, Svetlana Madjunkova, Clifford Librach,
Polycystic ovary syndrome (PCOS) is the most common reproductive disorder in women. MicroRNA (miRNA) plays important regulatory roles in PCOS development, but its biological mechanism remains poorly understood. Innovating the visualization methods of miRNA has great significance for studying the genesis and development of PCOS. Here, we report near-infrared (NIR) light-triggerable DNA nanoprobes (termed as LT-DP) for visualizing miRNA-103-associated molecular mechanisms in clinical ovarian...
Published on: Tue, 13 Jan 2026 06:00:00 -0500
Authors: Di Cheng, Jinli Ding, Bo Zhang, Shujie Liu, Xiaoming Zhang, Chen Xie, Yun Zhang, Zhipeng Gao, Fangrong Zhang, Erqun Song, Tailang Yin, Yanbing Yang, Quan Yuan,
Adrenocortical carcinoma (ACC) is a highly aggressive malignancy with poor survival rates and few treatment options. Preclinical models are indispensable to further strengthen our understanding of disease progression and development of novel therapeutic treatments. Here, we report the establishment of a new cell line named ZUC-1 originating from the resection of an advanced primary ACC and its characterization at the genomic, cellular and molecular level. ZUC-1 cells were successfully propagated...
Published on: Tue, 13 Jan 2026 06:00:00 -0500
Authors: Igor Shapiro, Chiara Kräuchi, Edlira Luca, Susanne Dettwiler, Mirko Peitzsch, Weihong Qi, Astrid Reul, Felix Beuschlein, Umberto Maccio, Svenja Nölting, Huguette Debaix, Constanze Hantel,
CONCLUSION: PCOS+MASLD in adolescents, but not PCOS alone, increases the likelihood of obesity, insulin resistance and an adverse cardiometabolic phenotype during adulthood.
Published on: Tue, 13 Jan 2026 06:00:00 -0500
Authors: Oyekoya T Ayonrinde, Trevor A Mori, Leon A Adams, Lawrence J Beilin, John K Olynyk, Roger Hart,
CONCLUSION: This study underscores the elevated levels of MEHP and DEHP in women with PCOS, highlighting the potential influence of these environmental toxins in PCOS pathogenesis.
Published on: Mon, 12 Jan 2026 06:00:00 -0500
Authors: Jalpa Patel, Hiral Chaudhary, Sonal Panchal, Kiransinh Rajput, Rushikesh Joshi,
CONCLUSION: SCH is a common and metabolically relevant comorbidity in women with PCOS, aggravating insulin resistance and dyslipi-demia without significantly affecting reproductive hormones. These findings highlight the need for routine thyroid function screening in PCOS management, especially among those with metabolic syndrome features. Further longitudinal studies are warranted to evaluate the benefits of targeted thyroid intervention in this subgroup.
Published on: Mon, 12 Jan 2026 06:00:00 -0500
Authors: Anand Acharya, Renu Sulakhe, Varada A Hasamnis, Abinash Panda,